Clinical trial supply strategies are rarely static. Recruitment rates change, forecasts evolve, and supply chain conditions can shift unexpectedly throughout the life of a study. In these situations, success depends on having a supply partner capable of adapting quickly while maintaining regulatory compliance, product availability, and operational continuity.
This case study demonstrates how BAP Pharma helped a sponsor overcome significant supply and packaging challenges during a multi-country Phase III clinical trial by implementing an agile comparator sourcing and packaging strategy that reduced risk, minimised waste, and kept patient recruitment on track.
The Challenge
A sponsor initially forecasted uncertain patient enrolment before experiencing significantly faster-than-expected patient enrolment. This created an urgent requirement for additional comparator medicines and an accelerated packaging schedule that exceeded the original supply plan.
The revised recruitment timelines introduced several operational risks, including:
- Insufficient product availability to support increased demand.
- Long procurement lead times from existing distribution channels.
- Tight batch expiry requirements.
- Pressure to complete additional packaging runs within compressed timelines.
- Increased risk of product wastage and unnecessary costs if large volumes were sourced using a traditional stock-building model.
Without a more agile approach, the sponsor faced the possibility of delayed packaging, interrupted patient recruitment, higher inventory costs, and increased waste.
The BAP Pharma Approach
BAP Pharma rapidly adapted its sourcing and packaging strategy to support the sponsor’s evolving requirements.
Rather than relying solely on traditional distributor channels, the Comparator Sourcing team evaluated multiple procurement options and successfully transitioned supply directly to the manufacturer. Working closely with the manufacturer, BAP Pharma negotiated reduced lead times while ensuring products met strict expiry requirements and were supplied with all necessary regulatory documentation.
At the same time, BAP Pharma’s Comparator Sourcing and Packaging & Labelling teams worked as one integrated operation, allowing sourcing decisions, packaging schedules and release timelines to be coordinated from the outset.
To further optimise the supply strategy, BAP Pharma implemented its agile “little and often” procurement model, enabling smaller, more frequent product purchases that aligned closely with actual patient demand.
Throughout the study, the team continuously monitored market conditions, supply risks and recruitment trends, adjusting sourcing plans whenever required to maintain uninterrupted supply.
In parallel, BAP Pharma implemented several waste reduction and inventory optimisation measures, including:
- Reducing inventory held in stock.
- Continuously monitoring market availability and negotiating improved shelf life and shorter lead times.
- Responding rapidly to changing recruitment without increasing stock-out risk.
- Delaying EU FMD decommissioning until required, preserving surplus stock as commercial product where appropriate.
- Reducing the overall number of packaging runs required during the study.
- Preventing product excursions by packaging at refrigerated temperature and at low light within the BAP Pharma German facility.
This fully integrated approach significantly reduced the time between product receipt and release while maintaining complete regulatory compliance.
The Outcome
By combining agile comparator sourcing with flexible packaging and labelling, BAP Pharma successfully maintained uninterrupted supply throughout the Phase III study despite substantial changes in recruitment demand.
Key outcomes included:
- Continuous product availability throughout the study.
- Packaging milestones delivered despite accelerated timelines.
- Reduced procurement lead times through direct manufacturer engagement.
- Fewer packaging runs than originally forecast, delivering significant operational efficiencies.
- Lower inventory holding and reduced product wastage.
- Improved cost efficiency across the study.
- Continued patient recruitment without interruption.
- Greater confidence in supply continuity through proactive risk management and ongoing market monitoring.
The sponsor was able to maintain study momentum while reducing both operational complexity and financial exposure.
Key Insight
Traditional bulk purchasing models are often poorly suited to modern clinical trials, where recruitment, forecasting and supply requirements can change rapidly.
An integrated, agile supply strategy—combining comparator sourcing, secondary packaging and labelling—provides sponsors with the flexibility to respond to changing study demands while reducing cost, waste and operational risk.
Why It Matters
Clinical development programmes increasingly require supply strategies that can adapt as quickly as the study itself.
By aligning procurement volumes with actual patient demand, sponsors can:
- Improve cash flow by avoiding unnecessary upfront inventory investment.
- Reduce waste associated with product expiry.
- Shorten packaging and release timelines.
- Respond rapidly to recruitment fluctuations.
- Strengthen supply chain resilience.
- Support more sustainable clinical trial operations through reduced excess inventory and improved resource utilisation.
For sponsors operating in increasingly complex global studies, flexibility has become a competitive advantage rather than simply an operational benefit.
BAP Pharma Perspective
At BAP Pharma, comparator sourcing, packaging and labelling are not treated as separate activities—they are delivered as one integrated solution.
Our agile “little and often” procurement model allows sponsors to build resilient clinical supply strategies that adapt to real-world study conditions. By combining proactive market intelligence, strategic sourcing, flexible packaging capabilities and continuous supply monitoring, we help sponsors minimise risk, reduce waste and maintain uninterrupted patient access throughout the clinical development journey.
Because when clinical trials change—as they inevitably do—your supply strategy should already be ready to change with them.
